Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

PRESERFLO MicroShunt

View through CrossRef
Abstract The PRESERFLO® MicroShunt (Santen Pharmaceutical Co. Ltd., Osaka, Japan), formerly called the InnFocus MicroShunt®, is a trans-scleral device that shunts aqueous humour from the anterior chamber to a filtering bleb under the conjunctiva and Tenon’s capsule. Manufactured from an inert biocompatible material called poly(styrene-block-isobutylene-block-styrene), or ‘SIBS’, the device elicits minimal foreign body reaction and inflammation; potentially reducing the risk of bleb-related fibrosis and failure. The MicroShunt is 8.5 mm long with a 70 μm lumen and is designed to minimize hypotony based on the Hagen–Poiseuille equation. Inserted via an ab-externo approach, the MicroShunt eliminates the need for creation of a scleral flap, sclerostomy, iridectomy, scleral flap suturing and postoperative suture lysis. Clinical trials show promising results with the MicroShunt achieving intraocular pressure reduction approaching that of trabeculectomy, the current gold standard for treating refractory glaucoma.
Title: PRESERFLO MicroShunt
Description:
Abstract The PRESERFLO® MicroShunt (Santen Pharmaceutical Co.
Ltd.
, Osaka, Japan), formerly called the InnFocus MicroShunt®, is a trans-scleral device that shunts aqueous humour from the anterior chamber to a filtering bleb under the conjunctiva and Tenon’s capsule.
Manufactured from an inert biocompatible material called poly(styrene-block-isobutylene-block-styrene), or ‘SIBS’, the device elicits minimal foreign body reaction and inflammation; potentially reducing the risk of bleb-related fibrosis and failure.
The MicroShunt is 8.
5 mm long with a 70 μm lumen and is designed to minimize hypotony based on the Hagen–Poiseuille equation.
Inserted via an ab-externo approach, the MicroShunt eliminates the need for creation of a scleral flap, sclerostomy, iridectomy, scleral flap suturing and postoperative suture lysis.
Clinical trials show promising results with the MicroShunt achieving intraocular pressure reduction approaching that of trabeculectomy, the current gold standard for treating refractory glaucoma.

Related Results

Staphylococcus Capitus Blebitis Following Preserflo MicroShunt Implantation
Staphylococcus Capitus Blebitis Following Preserflo MicroShunt Implantation
Purpose: To report a case of early-onset blebitis following Preserflo MicroShunt implantation. Patients and Methods: Case ...
Petrolatum-based ointment application induces swelling of the PRESERFLO Microshunt
Petrolatum-based ointment application induces swelling of the PRESERFLO Microshunt
Abstract Purpose To report the clinical cases of PRESERFLO MicroShunt swelling following exposure to petrolatum-based oph...
Clinical outcomes of combined Preserflo Microshunt implantation and cataract surgery in open-angle glaucoma patients
Clinical outcomes of combined Preserflo Microshunt implantation and cataract surgery in open-angle glaucoma patients
AbstractTo assess the effectiveness and safety of the Preserflo Microshunt (PMS) implantation combined with cataract surgery in open-angle glaucoma (OAG) patients. Retrospective, o...
In vivo evaluation of a nanotechnology-based microshunt for filtering glaucoma surgery
In vivo evaluation of a nanotechnology-based microshunt for filtering glaucoma surgery
AbstractTo carry out the preclinical and histological evaluation of a novel nanotechnology-based microshunt for drainage glaucoma surgery. Twelve New Zealand White rabbits were imp...

Back to Top